



(51) International Patent Classification:

B01D 15/16 (2006.01) B01J 20/281 (2006.01)
 B01D 15/20 (2006.01) G01N 30/56 (2006.01)
 B01D 15/36 (2006.01) G01N 30/72 (2006.01)
 B01D 15/38 (2006.01) B01D 15/32 (2006.01)
 G01N 30/34 (2006.01) G01N 30/96 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2019/056379

(22) International Filing Date:

25 July 2019 (25.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/711,093 27 July 2018 (27.07.2018) US

(71) Applicant: **WATERS TECHNOLOGIES CORPORATION** [US/US]; 34 Maple Street, Milford, Massachusetts 01757 (US).

(72) Inventors: **RAINVILLE, Paul D.**; 151 Brooks Station Road, Princeton, Massachusetts 01541 (US). **SMITH, Kerri M.**; 328 Hemenway Street, Marlborough, Massachusetts 01752 (US).

(74) Agent: **BARNES, Rebecca N.**; Womble Bond Dickinson (US) LLP, Two International Place, Suite 2310, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY METHODS FOR THE ANALYSIS OF POLAR MOLECULES

(57) Abstract: A mixed-mode chromatography method for the determination of phosphorylated sugars in a sample is provided. The mixed-mode chromatography method includes obtaining a sample comprising at least one phosphorylated sugar. The sample is introduced onto a chromatography system. The chromatography system includes a column having a stationary phase material contained inside the column. The stationary phase material has a surface comprising a hydrophobic surface group and at least one ionizable modifier. The sample with a mobile phase eluent is flowed through the column, where the at least one phosphorylated sugar is substantially resolved and retained within seven minutes. The mobile phase eluent includes water with an additive and acetonitrile with the additive. The mobile phase eluent has a pH less than 6. The at least one phosphorylated sugar is detected using a detector.



LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY METHODS FOR THE ANALYSIS OF POLAR MOLECULES

Cross-Reference to Related Applications

[0001] This application claims priority to and benefit of United States provisional patent application no. 62/711,093 filed on July 27, 2018 and entitled “Liquid Chromatography/Mass Spectrometry Methods for the Analysis of Polar Molecules,” the entire contents of which is hereby incorporated by reference.

Field of the Technology

[0002] The present disclosure relates to a liquid chromatography (LC)/mass spectrometry (MS) methods for the analysis of polar molecules. More specifically, the present disclosure relates to LC/MS methods for the analysis of phosphorylated sugars, amino acids, organic acids, and/or nucleotides.

Background

[0003] Obtaining chromatographic retention of acidic, highly-polar molecules such as organic acids, amino acids, phosphorylated sugars, and nucleotides can prove difficult with current chromatographic techniques. Current methodologies often incorporate the use of ion-pair reagents (Luo *et al*, Journal of Chromatography B, 1147, 2007, 153-164 and Lu *et al*, Analytical Chemistry, 2010, 82, 3212-3221), ion chromatography (IC) (for example Thermo Scientific® Dionex® ion chromatography system (commercially available from Thermo Fisher Scientific Inc. Waltham, MA, USA)), or hydrophilic interaction chromatography (HILIC) (Bajad *et al*, Journal of Chromatography A, 1125, 2006, 76-88). In addition, the use of derivatization can be carried out as a means to reduce the polarity of molecules (Tan *et al*, Analytical Biochemistry, 465, 2014, 134-147) and to thereby make it possible to retain, separate and subsequently detect these analytes for the purposes of quantitative or qualitative analyses. However, these current methods can suffer negative results due to sample or diluent restrictions, needing specialized equipment, or an incompatibility with mass spectrometric (MS) detection. Moreover, the process to prepare specialized mobile phases for use in these methods is laborious and time-consuming.

Summary

[0004] What is needed is a method to separate acidic polar molecules using common LC/MS techniques with standard mobile phases. The present technology solves the problems of the prior art by the use of charged surface hybrid (CSH) reversed phase/mixed-mode chromatographic materials along with standard reversed-phase LC and MS compatible conditions (e.g., mobile phases) for the retention and separation of phosphorylated sugars, amino acids, organic acids, and/or nucleotides. Improved methodologies in the analysis of these compounds is of importance to researchers, the medical community and pharmaceutical companies due to the direct involvement of these molecules in numerous disease states, such as cancer and diabetes. Further, the analysis of these molecules is of interest for the manufacturing of

various products from bioreactors. (Hinder *et al*, Journal of Endocrinology, 213, 2013, 1-11 and Rustin *et al*, Biochimica et Biophysica Acta, 1361, 1997, 185-197.)

[0005] The charged surface hybrid reversed phase/mixed-mode sorbents applicable to these separations have been defined in United States Patent Publication Number 20130319086A1 entitled “High Purity Chromatographic Materials Comprising an Ionizable Modifier” the contents of which is incorporated herein by reference. In brief, a charged surface reversed phase material is a high purity chromatographic material (HPCM) having a chromatographic surface comprised of a hydrophobic surface group and one or more ionizable modifiers. These charged surface reversed phase/mixed-mode materials can have a ratio of hydrophobic surface group:ionizable modifier in the HPCM from about 2.5:1 to about 350:1. In some embodiments, the ratio of hydrophobic surface group:ionizable modifier is between about 4:1 to about 350:1 or from about 4:1 to about 22:1 or from about 5:1 to about 22:1. The charged surface reversed phase materials can have a concentration of ionizable modifier in the HPCM that is less than about 0.5 $\mu\text{mol}/\text{m}^2$. In some embodiments, the concentration of ionizable modifier is between about 0.03 $\mu\text{mol}/\text{m}^2$ and 0.5 $\mu\text{mol}/\text{m}^2$.

[0006] The use of the CSH sorbents with a reversed-phase liquid chromatography column results in mixed-mode chromatography, where more than one form of interaction between the analyte and the stationary phase is used for separation of the sample. The use of the CSH sorbents results in both hydrophobic interactions between the analyte and the sorbent (e.g., from the hydrophobic surface group) as well as anion exchange interactions between the analyte and the sorbent (e.g., from the ionizable modifier). In this application, the technology is directed to a mixed-mode chromatographic method in which hydrophobic interactions are one of the forms of interactions used for the separation. As a result, the technology can be said to be a mixed-mode/reversed phase chromatography system and method.

[0007] In one aspect, the technology relates to a mixed-mode chromatography method for the determination of phosphorylated sugars in a sample. The mixed-mode chromatography method includes obtaining a sample comprising at least one phosphorylated sugar. The sample is introduced onto a chromatography system that includes a column having a stationary phase material contained inside the column. The stationary phase material has a surface comprising a hydrophobic surface group and at least one ionizable modifier. The sample with a mobile phase eluent is flowed through the column. The at least one phosphorylated sugar is substantially resolved and retained within seven minutes. The mobile phase eluent includes water with an additive and acetonitrile with the additive. The mobile phase eluent has a pH less than 6. The at least one phosphorylated sugar is detected using a detector. The method can include one or more of the following embodiments.

[0008] In some embodiments, the pH of the mobile phase eluent is less than 5. The pH of the mobile phase eluent can be less than 3. In some embodiments, the pH of the mobile phase eluent is between about 2.5 and 3. The pH of the mobile phase eluent can be about 2.7

[0009] In some embodiments, the additive is 0.1% formic acid. The additive can be a mass spectrometry compatible buffer. The mass spectrometry compatible buffer can be, for example, ammonium formate, ammonium acetate, or ammonium bicarbonate.

[0010] In one embodiment, the mobile phase eluent comprises a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile. The mobile phase eluent can have a linear or step gradient elution comprising a.) 100% mobile phase A, 0% mobile phase B at an initial time; b.) 70% mobile phase A, 30% mobile phase B at a time of 3 minutes; c.) 5% mobile phase A, 95% mobile phase B at a time of 3.5 minutes; d.) 5% mobile phase A, 95% mobile phase B at a time of 6.5 minutes; and e.) 100% mobile phase A, 0% mobile phase B at a time of 7 minutes.

[0011] The sample with the mobile phase eluent can be flowed through the column at a rate from 0.2-1.0 mL/min. In some embodiments, the sample with the mobile phase eluent is flowed through the column at a rate of about 0.4 mL/min.

[0012] The hydrophobic surface group can be a fluoro-phenyl functional group. The hydrophobic surface group can be a phenyl-hexyl functional group. In some embodiments, the hydrophobic surface group is a C₁₈ functional group.

[0013] In general, the detector can be a mass spectrometer.

[0014] In another aspect, the technology relates to a mixed-mode chromatography method for the determination of amino acids in a sample. The mixed mode chromatography method includes obtaining a sample including at least one amino acid. The sample is introduced onto a chromatography system including a column having a stationary phase material contained inside the column. The stationary phase material has a surface comprising a hydrophobic surface group and at least one ionizable modifier. The sample with a mobile phase eluent is flowed through the column. The at least one amino acid is substantially resolved and retained within seven minutes. The mobile phase eluent includes water with an additive (e.g., 0.1% formic acid) and acetonitrile with the additive (e.g., 0.1% formic acid). The mobile phase eluent has a pH less than 6. The at least one amino acid is detected using a detector. The method can include one or more of the following embodiments.

[0015] In some embodiments, the pH of the mobile phase eluent is less than 5. The pH of the mobile phase eluent can be less than 3. In some embodiments, the pH of the mobile phase eluent is between about 2.5 and 3. The pH of the mobile phase eluent can be about 2.7

[0016] In some embodiments, the additive is 0.1% formic acid. The additive can be a mass spectrometry compatible buffer.

[0017] In one embodiment, the mobile phase eluent comprises a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile. The mobile phase eluent can have a linear or step gradient elution comprising a.) 100% mobile phase A, 0% mobile phase B at an initial time; b.) 70% mobile phase A, 30% mobile phase B at a time of 3 minutes; c.)

5% mobile phase A, 95% mobile phase B at a time of 3.5 minutes; d.) 5% mobile phase A, 95% mobile phase B at a time of 6.5 minutes; and e.) 100% mobile phase A, 0% mobile phase B at a time of 7 minutes.

[0018] The sample with the mobile phase eluent can be flowed through the column at a rate from 0.2-1.0 mL/min. In some embodiments, the sample with the mobile phase eluent is flowed through the column at a rate of about 0.4 mL/min.

[0019] The hydrophobic surface group can be a fluoro-phenyl functional group. The hydrophobic surface group can be a phenyl-hexyl functional group. In some embodiments, the hydrophobic surface group is a C₁₈ functional group.

[0020] In general, the detector can be a mass spectrometer.

[0021] In some embodiments, the at least one amino acid is one or more of glutamate, glutamine, isoleucine, or leucine.

[0022] In another aspect, the technology relates to a mixed-mode chromatography method for the determination of organic acids in a sample. The mixed mode chromatography method includes obtaining a sample comprising at least one organic acid. The sample is introduced onto a chromatography system including a column having a stationary phase material contained inside the column. The stationary phase material has a surface comprising a fluoro-phenyl hydrophobic surface group and an ionizable modifier. The sample with a mobile phase eluent is flowed through the column. The at least one organic acid is substantially resolved and retained within seven minutes. The mobile phase eluent includes a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile. The mobile phase eluent has a pH less than 6. The at least one organic acid is detected using a detector. The method can include any of the embodiments described herein.

[0023] The at least one organic acid can be one or more of isocitric acid, aconitic acid, α-ketoglutaric acid, lactic acid, or pyruvic acid.

[0024] This technology provides numerous advantages. For example, the technology allows for the separation of phosphorylated sugars, organic acids, amino acids and/or nucleotides in a quick manner, for example, under seven minutes. In addition, the technology allows for the separation of these analytes using common LC/MS techniques with standard mobile phases (e.g., water with 0.1% formic acid and acetonitrile with 0.1% formic acid), which are commonly available in analytical laboratories.

Brief Description of the Drawings

[0025] The technology will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

[0026] **FIG. 1** is a flow chart of a mixed-mode chromatography method for the determination of a phosphorylated sugar, an amino acid and/or an organic acid in a sample, according to an illustrative embodiment of the technology.

- [0027] **FIG. 2** is a schematic of a mixed-mode chromatography system, according to an illustrative embodiment of the technology.
- [0028] **FIG. 3A** is an MRM chromatogram for the separation of isocitric acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0029] **FIG. 3B** is an MRM chromatogram for the separation of citric acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0030] **FIG. 3C** is an MRM chromatogram for the separation of aconitic acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0031] **FIG. 3D** is an MRM chromatogram for the separation of alpha ketoglutaric acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0032] **FIG. 3E** is an MRM chromatogram for the separation of succinic acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0033] **FIG. 3F** is an MRM chromatogram for the separation of malic acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0034] **FIG. 3G** is an MRM chromatogram for the separation of fumaric acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0035] **FIG. 3H** is an MRM chromatogram for the separation of lactic acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0036] **FIG. 3I** is an MRM chromatogram for the separation of pyruvate acid, a TCA cycle analyte, on CSH C₁₈ 100μM STD, according to an illustrative embodiment of the technology.
- [0037] **FIG. 4A** is an MRM chromatogram for the separation of isocitric acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.
- [0038] **FIG. 4B** is an MRM chromatogram for the separation of citric acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.
- [0039] **FIG. 4C** is an MRM chromatogram for the separation of aconitic acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.
- [0040] **FIG. 4D** is an MRM chromatogram for the separation of alpha ketoglutaric acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.
- [0041] **FIG. 4E** is an MRM chromatogram for the separation of succinic acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.
- [0042] **FIG. 4F** is an MRM chromatogram for the separation of malic acid, a TCA cycle analyte, on CSH phenyl hexyl 100μM STD, according to an illustrative embodiment of the technology.

- [0043] **FIG. 4G** is an MRM chromatogram for the separation of fumaric acid, a TCA cycle analyte, on CSH phenyl hexyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0044] **FIG. 4H** is an MRM chromatogram for the separation of lactic acid, a TCA cycle analyte, on CSH phenyl hexyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0045] **FIG. 4I** is an MRM chromatogram for the separation of pyruvate acid, a TCA cycle analyte, on CSH phenyl hexyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0046] **FIG. 5A** is an MRM chromatogram for the separation of isocitric acid, a TCA cycle analyte, on CSH phenyl hexyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0047] **FIG. 5B** is an MRM chromatogram for the separation of citric acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0048] **FIG. 5C** is an MRM chromatogram for the separation of aconitic acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0049] **FIG. 5D** is an MRM chromatogram for the separation of alpha ketoglutaric acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0050] **FIG. 5E** is an MRM chromatogram for the separation of succinic acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0051] **FIG. 5F** is an MRM chromatogram for the separation of malic acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0052] **FIG. 5G** is an MRM chromatogram for the separation of fumaric acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0053] **FIG. 5H** is an MRM chromatogram for the separation of lactic acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0054] **FIG. 5I** is an MRM chromatogram for the separation of pyruvate acid, a TCA cycle analyte, on CSH fluoro phenyl 100 μ M STD, according to an illustrative embodiment of the technology.
- [0055] **FIG. 6A** is a chromatogram for the separation of TCA cycle metabolites using a BEH C₁₈ column, according to an illustrative embodiment of the technology.
- [0056] **FIG. 6B** is a chromatogram for the separation of TCA cycle metabolites using a CSH C₁₈ column, according to an illustrative embodiment of the technology.
- [0057] **FIG. 6C** is a chromatogram for the separation of TCA cycle metabolites using a CSH phenyl-hexyl column, according to an illustrative embodiment of the technology.
- [0058] **FIG. 7A** is a chromatogram for the separation of glutamate acid using a CSH C₁₈ STD column, according to an illustrative embodiment of the technology.

- [0059] **FIG. 7B** is a chromatogram for the separation of glutamine acid using a CSH C₁₈ STD column, according to an illustrative embodiment of the technology.
- [0060] **FIG. 7C** is a chromatogram for the separation of isoleucine acid using a CSH C₁₈ STD column, according to an illustrative embodiment of the technology.
- [0061] **FIG. 7D** is a chromatogram for the separation of leucine acid using a CSH C₁₈ STD column, according to an illustrative embodiment of the technology.
- [0062] **FIG. 8A** is a chromatogram for the separation of glutamate acid using a CSH phenyl hexyl STD column, according to an illustrative embodiment of the technology.
- [0063] **FIG. 8B** is a chromatogram for the separation of glutamine acid using a CSH phenyl hexyl STD column, according to an illustrative embodiment of the technology.
- [0064] **FIG. 8C** is a chromatogram for the separation of isoleucine acid using a CSH phenyl hexyl STD column, according to an illustrative embodiment of the technology.
- [0065] **FIG. 8D** is a chromatogram for the separation of leucine acid using a CSH phenyl hexyl STD column, according to an illustrative embodiment of the technology.
- [0066] **FIG. 9A** is a chromatogram for the separation of glutamate acid using a CSH fluoro phenyl STD column, according to an illustrative embodiment of the technology.
- [0067] **FIG. 9B** is a chromatogram for the separation of glutamine acid using a CSH fluoro phenyl STD column, according to an illustrative embodiment of the technology.
- [0068] **FIG. 9C** is a chromatogram for the separation of isoleucine acid using a CSH fluoro phenyl STD column, according to an illustrative embodiment of the technology.
- [0069] **FIG. 9D** is a chromatogram for the separation of leucine acid using a CSH fluoro phenyl STD column, according to an illustrative embodiment of the technology.
- [0070] **FIG. 10A** is a chromatogram for the separation of methylmalonic acid using a CSH C₁₈ column, according to an illustrative embodiment of the technology.
- [0071] **FIG. 10B** is a chromatogram for the separation of succinic acid using a CSH C₁₈ column, according to an illustrative embodiment of the technology.
- [0072] **FIG. 10C** is a chromatogram for the separation of aconitic acid using a CSH C₁₈ column, according to an illustrative embodiment of the technology.
- [0073] **FIG. 10D** is a chromatogram for the separation of itaconic acid using a CSH C₁₈ column, according to an illustrative embodiment of the technology.
- [0074] **FIG. 11A** is a chromatogram for the separation of methylmalonic acid using a CSH phenyl hexyl column, according to an illustrative embodiment of the technology.

[0075] **FIG. 11B** is a chromatogram for the separation of succinic acid using a CSH phenyl hexyl column, according to an illustrative embodiment of the technology.

[0076] **FIG. 11C** is a chromatogram for the separation of aconitic acid using a CSH phenyl hexyl column, according to an illustrative embodiment of the technology.

[0077] **FIG. 11D** is a chromatogram for the separation of itaconic acid using a CSH phenyl hexyl column, according to an illustrative embodiment of the technology.

[0078] **FIG. 12A** is a chromatogram for the separation of methylmalonic acid using a CSH fluoro phenyl column, according to an illustrative embodiment of the technology.

[0079] **FIG. 12B** is a chromatogram for the separation of succinic acid using a CSH fluoro phenyl column, according to an illustrative embodiment of the technology.

[0080] **FIG. 12C** is a chromatogram for the separation of aconitic acid using a CSH fluoro phenyl column, according to an illustrative embodiment of the technology.

[0081] **FIG. 12D** is a chromatogram for the separation of itaconic acid using a CSH fluoro phenyl column, according to an illustrative embodiment of the technology.

[0082] **FIG. 13A** is a chromatogram for the separation of glucose 6 phosphate using a CSH C₁₈ column, according to an illustrative embodiment of the technology.

[0083] **FIG. 13B** is a chromatogram for the separation of glucose 6 phosphate using a CSH phenyl hexyl column, according to an illustrative embodiment of the technology.

[0084] **FIG. 13C** is a chromatogram for the separation of glucose 6 phosphate using a CSH fluoro phenyl column, according to an illustrative embodiment of the technology.

Detailed Description

[0085] The technology provides methods for chromatography separation and detection of polar molecules, for example, phosphorylated sugars, amino acids, organic acids, and/or nucleotides using a mixed-mode or reversed-phase chromatography column that includes a stationary phase material having a surface comprising a hydrophobic surface group and at least one ionizable modifier.

DEFINITIONS

[0086] As used herein, the term “about” means that the numerical value is approximate and small variations would not significantly affect the practice of the disclosed embodiments. Where a numerical limitation is used, unless indicated otherwise by the context, “about” means the numerical value can vary by $\pm 10\%$ and remain within the scope of the disclosed embodiments.

[0087] As used herein, the term “high purity” or “high purity chromatographic material” includes a material which is prepared from high purity precursors. In certain aspects, high purity materials have

reduced metal contamination and/or non-diminished chromatographic properties including, but not limited to, the acidity of surface silanols and the heterogeneity of the surface.

[0088] As used herein, the term “chromatographic surface” includes a surface which provides for chromatographic separation of a sample. In certain aspects, the chromatographic surface is porous. In some aspects, a chromatographic surface can be the surface of a particle, a superficially porous material or a monolith. In certain aspects, the chromatographic surface is composed of the surface of one or more particles, superficially porous materials or monoliths used in combination during a chromatographic separation. In certain other aspects, the chromatographic surface is non-porous.

[0089] As used herein, the term “ionizable modifier” includes a functional group which bears an electron donating or electron withdrawing group. In certain aspects, the ionizable modifier contains one or more carboxylic acid groups, amino groups, imido groups, amido groups, pyridyl groups, imidazolyl groups, ureido groups, thionyl-ureido groups or aminosilane groups, or a combination thereof. In other aspects, the ionizable modifier contains a group bearing a nitrogen or phosphorous atom having a free electron lone pair. In certain aspects, the ionizable modifier is covalently attached to the material surface and has an ionizable group. In some instances it is attached to the chromatographic material by chemical modification of a surface hybrid group.

[0090] As used herein, the term “hydrophobic surface group” includes a surface group on the chromatographic surface which exhibits hydrophobicity. In certain aspects, a hydrophobic group can be a carbon bonded phase such as a C₄ to C₁₈ bonded phase. In other aspects, a hydrophobic surface group can contain an embedded polar group such that the external portion of the hydrophobic surface maintains hydrophobicity. In some instances it is attached to the chromatographic material by chemical modification of a surface hybrid group. In other instances the hydrophobic group can be C₄-C₃₀, embedded polar, chiral, phenylalkyl, or pentafluorophenyl bonding and coatings.

[0091] As used herein, the term “hybrid”, including “hybrid inorganic/organic material,” includes inorganic-based structures wherein an organic functionality is integral to both the internal or “skeletal” inorganic structure as well as the hybrid material surface. The inorganic portion of the hybrid material may be, e.g., alumina, silica, titanium, cerium, or zirconium or oxides thereof, or ceramic material.

[0092] “Hybrid” includes inorganic-based structures wherein an organic functionality is integral to both the internal or “skeletal” inorganic structure as well as the hybrid material surface. As noted above, exemplary hybrid materials are shown in U.S. Pat. Nos. 4,017,528, 6,528,167, 6,686,035 and 7,175,913, the contents of each of which are incorporated hereby by reference.

[0093] As used herein, the term “surface modifiers” include (typically) organic functional groups which impart a certain chromatographic functionality to a chromatographic stationary phase. The porous inorganic/organic hybrid materials possess both organic groups and silanol groups which may additionally be substituted or derivatized with a surface modifier.

[0094] The language “surface modified” is used herein to describe the composite material of the present technology that possess both organic groups and silanol groups which may additionally be substituted or derivatized with a surface modifier. “Surface modifiers” include (typically) organic functional groups which impart a certain chromatographic functionality to a chromatographic stationary phase. Surface modifiers such as disclosed herein are attached to the base material, e.g., via derivatization or coating and later crosslinking, imparting the chemical character of the surface modifier to the base material. In one embodiment, the organic groups of a hybrid material, react to form an organic covalent bond with a surface modifier. The modifiers can form an organic covalent bond to the material's organic group via a number of mechanisms well known in organic and polymer chemistry including but not limited to nucleophilic, electrophilic, cycloaddition, free-radical, carbene, nitrene, and carbocation reactions. Organic covalent bonds are defined to involve the formation of a covalent bond between the common elements of organic chemistry including but not limited to hydrogen, boron, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur, and the halogens. In addition, carbon-silicon and carbon-oxygen-silicon bonds are defined as organic covalent bonds, whereas silicon-oxygen-silicon bonds that are not defined as organic covalent bonds. A variety of synthetic transformations are well known in the literature, see, e.g., March, *J. Advanced Organic Chemistry*, 3rd Edition, Wiley, New York, 1985.

METHODS

[0095] **FIG. 1** is a flow chart of a reversed phase or mixed-mode chromatography method **100** for the determination of phosphorylated sugars, amino acids, and/or organic acids in a sample. In some embodiments, the amino acid is glutamate, glutamine, isoleucine, or leucine. In some embodiments, the organic acid is a metabolite or intermediate of the tricarboxylic acid (TCA) cycle, for example, isocitric, citric, aconitic, a-ketoglutaric, succinic, malic, fumaric, lactic, pyruvic acid.

[0096] The reversed-phase/mixed mode chromatography method **100** includes obtaining a sample that includes the phosphorylated sugars, amino acids, and/or organic acids **105**. In some embodiments, the sample includes phosphorylated sugars, amino acids, and organic acids. The sample can include one of a phosphorylated sugar, amino acid or organic acid, or any combination thereof. In some embodiments, the sample includes multiple different types of sugars, amino acids, and/or organic acids. In other embodiments, the sample can also include a nucleotide.

[0097] The sample is introduced **110** to a reversed-phase/mixed-mode chromatography system. **FIG. 2** is a schematic of an exemplary reversed-phase or mixed-mode chromatography system **200**. The reversed-phase or mixed-mode chromatography system **200** includes a mobile phase reservoir **205** that stores a mobile phase eluent or multiple mobile phase eluents. A pump **210**, pumps the mobile phase eluent(s) from the mobile phase reservoir **205** to the reversed-phase or mixed-mode chromatography column **215**. A sample **220** is introduced into the mobile phase eluent flow stream prior to the reversed-phase or mixed-mode chromatography column **215**. The sample **220** and the mobile phase combine prior to entering the reversed-phase or mixed-mode chromatography column **215**, and form a combined flow stream.

[0098] The mobile phase eluent includes water with an additive and acetonitrile with an additive. The additive can be formic acid. In some embodiments, the additive is 0.1% formic acid. The additive can be a buffer that is compatible with mass spectrometry. The mobile phase eluent can consist of two separate mobile phases, mobile phase A and mobile phase B. Mobile phase A can consist essentially of 0.1% formic acid in water and mobile phase B can consist essentially of 0.1% formic acid in acetonitrile.

[0099] The mobile phase eluent can have a linear or step gradient elution. The linear or step gradient elution can be a. 100% mobile phase A, 0% mobile phase B at an initial time; b. 70% mobile phase A, 30% mobile phase B at a time of 3 minutes; c. 5% mobile phase A, 95% mobile phase B at a time of 3.5 minutes; d. 5% mobile phase A, 95% mobile phase B at a time of 6.5 minutes; and e. 100% mobile phase A, 0% mobile phase B at a time of 7 minutes.

[00100] The mobile phase eluent can have a flow rate between about 0.2 to about 1.0 mL/min. The mobile phase eluent flow rate can be about 0.2 mL/min, 0.3 mL/min, 0.4 mL/min, 0.5 mL/min, 0.6 mL/min, 0.7 mL/min, 0.8 mL/min, 0.9 mL/min, or 1.0 mL/min. These values can be used to define a range. In some embodiments the flow rate of the mobile phase eluent is about 0.40 mL/min.

[00101] The mobile phase eluent has a pH less than 6. In some embodiments the pH of the mobile phase eluent is less than 5. In other embodiments, the pH of the mobile phase eluent is less than 3. The pH of the mobile phase eluent can be 2.7. The pH of the mobile phase eluent can be 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0. These values can be used to define a range.


[00102] The reversed-phase or mixed-mode chromatography column **215** contains a stationary phase inside the column **215**. The stationary phase material has a surface that includes a hydrophobic surface group and an ionizable modifier. In some embodiment, the hydrophobic surface group contains a phenyl functional group. The phenyl functional group can include unsubstituted and substituted phenyl groups. The stationary phase can include a fluoro-phenyl functional group or a phenyl-hexyl functional group. The stationary phase material can include inorganic/organic hybrid particles or ethylene bridged hybrid particles. The mean particle size can measure about 0.1 μm , 0.2 μm , 0.3 μm , 0.4 μm , 0.5 μm , 0.6 μm , 0.7 μm , 0.8 μm , 0.9 μm , 1.0 μm , 1.1 μm , 1.2 μm , 1.3 μm , 1.4 μm , 1.5 μm , 1.6 μm , 1.7 μm , 1.8 μm , 1.9 μm , 2.0 μm , 2.1 μm , 2.2 μm , 2.3 μm , 2.4 μm , 2.5 μm , 2.6 μm , 2.7 μm , 2.8 μm , 2.9 μm , 3.0 μm , 3.1 μm , 3.2 μm , 3.3 μm , 3.4 μm , 3.5 μm , 3.6 μm , 3.7 μm , 3.8 μm , 3.9 μm , 4.0 μm , 4.1 μm , 4.2 μm , 4.3 μm , 4.4 μm , 4.5 μm , 4.6 μm , 4.7 μm , 4.8 μm , 4.9 μm , 5.0 μm , 5.1 μm , 5.2 μm , 5.3 μm , 5.4 μm , 5.5 μm , 5.6 μm , 5.7 μm , 5.8 μm , 5.9 μm , 6.0 μm , 6.5 μm , 7.0 μm , 7.5 μm , 8.0 μm , 8.5 μm , 9.0 μm , 9.5 μm , 10.0 μm , 10.5 μm , 11.0 μm , 11.5 μm , 12.0 μm , 12.5 μm , 13.0 μm , 13.5 μm , 14.0 μm , 14.5 μm , or 15 μm . These values can define a range. In one embodiment, the particle size is about 1.7 μm .

[00103] The functional group imparts a certain chromatographic functionality to a chromatographic stationary phase material. The hydrophobic surface group is attached to the base material (particle), for example, via derivatization or coating and later crosslinking, imparting the chemical character of the


hydrophobic surface group or functional group to the base material (e.g., the inorganic/organic hybrid particles or ethylene bridged hybrid particles described above).

[00104] The ionizable modifiers and hydrophobic surface groups can be applied to a base particle using a variety of methods. For example, starting with an unbonded based particle (e.g., ethylene bridged hybrid particle (BEH)), a small controlled charge can be applied to the BEH particle surface. The resulting charged surface hybrid (CSH) particle can be then bonded and sometimes endcapped with the functional group, for example, a fluoro-phenyl functional group, a phenyl-hexyl functional group or a C₁₈ functional group.


[00105] The inorganic/organic hybrid particles possess both organic groups and silanol groups which can additionally be substituted or derivatized with a surface modifier. “Surface modifiers” include (typically) organic functional groups which impart a certain chromatographic functionality to a chromatographic stationary phase. The surface modifier can be, for example, a C₁₈ group, unsubstituted and substituted phenyl groups, a fluoro-phenyl, or phenyl-hexyl functional group. Examples of these functional groups are shown below.



Example of a stationary phase having a C₁₈ functional group.



Example of a stationary phase having a fluoro-phenyl functional group.



Example of a stationary phase having a phenyl-hexyl functional group.

[00106] Table 1 shows the properties of charged surface hybrid (CSH) bonded with C₁₈, fluoro-phenyl or phenyl-hexyl functional groups.

TABLE 1: Properties of CSH Bonded Phases

	Surface Concentration ($\mu\text{mol}/\text{m}^2$)	Endcapping	% C	pH Range
CSH C ₁₈	2.3	yes	15.5	1 - 11
CSH Phenyl-Hexyl	2.3	yes	13.5	1 - 11
CSH Fluoro-Phenyl	2.3	no	10.2	1 - 8

[00107] The anion-exchange characteristics of CSH bonded phases make them useful for separating polar acidic compounds (e.g., phosphorylated sugars, amino acids, organic acids, and/or nucleotides), which are typically poorly retained on reversed-phase columns. This is demonstrated for a number of different types of analytes in the Examples.

[00108] Referring back to **FIG. 2**, the reversed-phase chromatography column **215** can have any inner diameter that allows for the efficient separation of acidic polar compounds, e.g., phosphorylated sugars, amino acids, organic acids, and/or nucleotides. The inner diameter of the chromatography column **215** can be, for example, 0.05 mm, 0.075 mm, 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.0 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.1 mm, 2.2 mm, 2.3 mm, 2.4 mm, 2.5 mm, 2.6 mm, 2.7 mm, 2.8 mm, 2.9 mm, or 3 mm. These values can be used to define a range. In some embodiments, the inner diameter of the reversed-phase chromatography column **215** is 2.1 mm.

[00109] Similarly, the reversed-phase chromatography column **215** can have any length that allows for the separation of acidic polar compounds, e.g., phosphorylated sugars, amino acids, organic acids, and/or nucleotides. The length can be, for example, about 5 mm, 10 mm, 20 mm, 25 mm, 30 mm, 35 mm, 40 mm, 45 mm, 50 mm, 55 mm, 60 mm, 65 mm, 70 mm, 75 mm, 80 mm, 85 mm, 90 mm, 95 mm, 100 mm, 105 mm, 110 mm, 115 mm, 120 mm, 125 mm, 150 mm, 200 mm, 250 mm, or 300 mm. These values can be used to define a range. In some embodiments, the length of the reversed-phase chromatography column **215** is 100 mm.

[00110] The reversed-phase chromatography system **200** can have a detector **222** positioned downstream of the column **215**. The detector **222** can be used to detect the acidic polar compounds, e.g., phosphorylated sugars, amino acids, organic acids, and/or nucleotides eluting from the reversed-phase or mixed-mode chromatography column **215**. The detector **222** can be a mass spectrometer. In some embodiments, the detector **222** is a tandem mass spectrometer (MS/MS). The detector can be a tandem quadrupole mass spectrometer.

[00111] A data acquisition module **225** can be in communication with the detector **222**. The data acquisition module **225** can be used, for example, to gather/collect and analyze data received from the detector **222**. The data acquisition module **225** can be a computer having software installed to collect and analyze the data.

[00112] Referring back to **FIG. 1**, the sample and mobile phase eluent (combined flow stream) are flowed **115** through the reversed-phase/mixed-mode chromatography column (e.g., column **215** of **FIG. 2**). The acidic polar compounds, e.g., phosphorylated sugars, amino acids, organic acids, and/or nucleotides are substantially resolved and retained on the column. In some embodiments, the phosphorylated sugars, amino acids, organic acids, and/or nucleotides are separated in about 7 minutes.


[00113] The retention time, resolution from other analytes in the sample and selectivity of analytes in a chromatography separation can be influenced by a number of factors. These factors can include the strong eluent or mobile phase, the pH of the sample and mobile phase as well as the profile and duration of the gradient. For example, a positively charged sorbent (e.g., a CSH sorbent) will attract negatively charged molecules (e.g., organic acids, phosphorylated sugars, amino acids and nucleotides). Therefore, these negatively charged analytes will be attracted to and retained on a positively charged sorbent. The mobile phase gradient can then be manipulated or changed to selectively release the negatively charged analytes to elute from the column. For example, decreasing the pH of the mobile phase eluent over time will result in the negatively charged analytes being released from the stationary phase material and will elute from the column.

[00114] The phosphorylated sugars, amino acids, organic acids, and/or nucleotides are detected **120** using a detector or multiple detectors, for example, detector **222** of **FIG. 2**. The detector can be used to detect the phosphorylated sugars, amino acids, organic acids, and/or nucleotides eluting from the reversed-phase/mixed mode chromatography column. The detector can be a mass spectrometer.

EXAMPLES

[00115] **Example 1: Metabolites and Intermediates of the Tricarboxylic Acid (TCA) Cycle**

[00116] Standards were prepared in water and diluted with water to make a solution of 100 μ molar for metabolites and intermediates of the tricarboxylic acid (TCA) cycle, for example, isocitric, citric, aconitic, α -ketoglutaric, succinic, malic, fumaric, lactic and pyruvic organic acids. The structures of these metabolites and intermediates of the tricarboxylic acid (TCA) cycle are shown below.



[00117] Samples were injected onto an LC/MS system in neat solution and spiked into human plasma treated with dipotassium ethylenediaminetetraacetic acid (K2EDTA). These analytes were then separated using an ACQUITY® UPLC® I-Class LC system (commercially available from Waters Technologies Corporation, Milford, MA USA) coupled with a Xevo® TQ S tandem quadrupole mass spectrometer operated in ESI negative mode and in MRM acquisition mode (commercially available from Waters Technologies Corporation, Milford, MA USA). Details of the method are described in Tables 2 and 3.

TABLE 2: Liquid Chromatography Conditions

Columns	ACQUITY® UPLC® CSH C ₁₈ column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Phenyl-Hexyl column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Fluoro-Phenyl column; 130Å 1.7µm 2.1 x 100 mm (commercially available from Waters Technologies Corporation, Milford, MA USA)
Mobile Phase A	100% water, 0.1% formic acid (v/v)
Mobile Phase B	100% acetonitrile, 0.1% formic acid (v/v)
Column Temperature	50°C
Injection Volume	3µL
Sample Diluent	Water
Detection	Tandem quadrupole MS MRM mode ESI negative mode

TABLE 3: Gradient Table

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	0.40	100.0	0.00	Initial
3.00	0.40	70	30.0	6
3.50	0.40	5.0	95.0	6
6.50	0.40	5.0	95.0	6
7.00	0.40	100.0	0.0	6

[00118] **FIGs. 3A-3I** present MRM chromatograms of various TCA cycle metabolites and intermediates and the effectiveness of a mixed mode separations using a CSH C₁₈ column at 100μM STD. **FIG. 3A** shows the MRM chromatogram for isocitric acid. **FIG. 3B** shows the MRM chromatogram for citric acid. **FIG. 3C** shows the MRM chromatogram for aconitic acid. **FIG. 3D** shows the MRM chromatogram for alpha ketoglutaric acid. **FIG. 3E** shows the MRM chromatogram for succinic acid. **FIG. 3F** shows the MRM chromatogram for malic acid. **FIG. 3G** shows the MRM chromatogram for fumaric acid. **FIG. 3H** shows the MRM chromatogram for lactic acid. **FIG. 3I** shows the MRM chromatogram for pyruvate acid.

[00119] **FIGs. 4A-4I** present MRM chromatograms of various TCA cycle metabolites and intermediates and the effectiveness of a mixed mode separations using a CSH phenyl hexyl column at 100μM STD. **FIG. 4A** shows the MRM chromatogram for isocitric acid. **FIG. 4B** shows the MRM chromatogram for citric acid. **FIG. 4C** shows the MRM chromatogram for aconitic acid. **FIG. 4D** shows the MRM chromatogram for alpha ketoglutaric acid. **FIG. 4E** shows the MRM chromatogram for succinic acid. **FIG. 4F** shows the MRM chromatogram for malic acid. **FIG. 4G** shows the MRM chromatogram for fumaric acid. **FIG. 4H** shows the MRM chromatogram for lactic acid. **FIG. 4I** shows the MRM chromatogram for pyruvate acid.

[00120] **FIGs. 5A-5I** present MRM chromatograms of various TCA cycle metabolites and intermediates and the effectiveness of a mixed mode separations using a CSH fluoro phenyl column at 100μM STD. **FIG. 5A** shows the MRM chromatogram for isocitric acid. **FIG. 5B** shows the MRM chromatogram for citric acid. **FIG. 5C** shows the MRM chromatogram for aconitic acid. **FIG. 5D** shows the MRM chromatogram for alpha ketoglutaric acid. **FIG. 5E** shows the MRM chromatogram for succinic acid. **FIG. 5F** shows the MRM chromatogram for malic acid. **FIG. 5G** shows the MRM chromatogram for fumaric acid. **FIG. 5H** shows the MRM chromatogram for lactic acid. **FIG. 5I** shows the MRM chromatogram for pyruvate acid.

[00121] The metabolites in the TCA cycle are highly polar, most containing two or three carboxylic acid groups (see structures above). The pK_a values of the most acidic groups in these molecules range from approximately 2.8 to 3.8. They are poorly retained on conventional reversed-phase columns. It was determined that these compounds were retained on the three CSH materials, using a mobile phase containing 0.1% formic acid in water and in acetonitrile. As shown by comparing **FIGs. 3A-I, 4A-I and 5A-I**, the most promising results were obtained using the CSH phenyl hexyl column. While the CSH fluoro-phenyl column showed greater retention of these analytes, several exhibited poor peak shapes under these conditions.

[00122] FIGs. 6A-C show chromatograms of the separation of TCA cycle metabolites using a BEH C₁₈ column (FIG. 6A), a CSH C₁₈ column (FIG. 6B) and a CSH phenyl-hexyl column (FIG. 6C). The columns were all 1.7 μ m 2.1 x 100 mm columns. In each of these figures, 1 is isocitric acid, 2 is malic acid, 3 is alpha-ketoglutaric acid, 4 is lactic acid, 5 is citric acid, 6 is fumaric acid, 7 is aconitric acid, and 8 is succinic acid.

[00123] The CSH columns have significant retention for anions when the mobile pH is less than 5, with retention increasing as the pH is decreased. The relative retention of anions increases from CSH C₁₈ < CSH phenyl-hexyl < CSH fluoro-phenyl. The ability to retain anions makes CSH columns useful for the separation of polar acids such as the TCA cycle metabolites.

[00124] Example 2: Amino Acids

[00125] Standards were prepared in water and diluted with water to make a solution of 100 μ Molar for glutamine and glutamate and 10 μ g/mL for leucine and isoleucine. These analytes were then separated using an ACQUITY® UPLC® I-Class LC system (commercially available from Waters Technologies Corporation, Milford, MA USA) coupled with a Xevo® TQ S tandem quadrupole mass spectrometer operated in ESI negative mode and in MRM acquisition mode (commercially available from Waters Technologies Corporation, Milford, MA USA). Details of the method are described in Tables 4 and 5.

TABLE 4: Liquid Chromatography Conditions

Columns	ACQUITY® UPLC® CSH C ₁₈ column; 130Å 1.7 μ m 2.1 x 100 mm ACQUITY® UPLC® CSH Phenyl-Hexyl column; 130Å 1.7 μ m 2.1 x 100 mm ACQUITY® UPLC® CSH Fluoro-Phenyl column; 130Å 1.7 μ m 2.1 x 100 mm (commercially available from Waters Technologies Corporation, Milford, MA USA)
Mobile Phase A	100% water, 0.1% formic acid (v/v)
Mobile Phase B	100% acetonitrile, 0.1% formic acid (v/v)
Column Temperature	50°C
Injection Volume	3 μ L
Sample Diluent	Water
Detection	Tandem quadrupole MS MRM mode ESI negative mode

TABLE 5: Gradient Table

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	0.40	100.0	0.00	Initial
3.00	0.40	70	30.0	6
3.50	0.40	5.0	95.0	6
6.50	0.40	5.0	95.0	6
7.00	0.40	100.0	0.0	6

[00126] **FIGs. 7A-7D** show the analysis of amino acids using a CSH C₁₈ STD sorbent in a reversed phase column. **FIG. 7A** shows the MRM chromatogram for glutamic acid. **FIG. 7B** shows the MRM chromatogram for glutamine acid. **FIG. 7C** shows the MRM chromatogram for isoleucine acid. **FIG. 7D** shows the MRM chromatogram for leucine acid.

[00127] **FIGs. 8A-8D** show the analysis of amino acids using a CSH phenyl hexyl STD sorbent in a reversed phase column. **FIG. 8A** shows the MRM chromatogram for glutamic acid. **FIG. 8B** shows the MRM chromatogram for glutamine acid. **FIG. 8C** shows the MRM chromatogram for isoleucine acid. **FIG. 8D** shows the MRM chromatogram for leucine acid.

[00128] **FIGs. 9A-9D** show the analysis of amino acids using a CSH fluoro phenyl STD sorbent in a reversed phase column. **FIG. 9A** shows the MRM chromatogram for glutamic acid. **FIG. 9B** shows the MRM chromatogram for glutamine acid. **FIG. 9C** shows the MRM chromatogram for isoleucine acid. **FIG. 9D** shows the MRM chromatogram for leucine acid.

[00129] As can be seen from a comparison of FIGs. 7-9, the CSH phenyl hexyl column showed increased separation and retention for glutamate and glutamine compared to the CSH C₁₈ column. Moreover, the CSH fluoro phenyl column showed increased separation and retention for glutamate and glutamine compared to both the CSH C₁₈ column and the CSH phenyl hexyl column.

[00130] In contrast, the opposite result can be seen for isoleucine and leucine where the CSH phenyl hexyl column showed decreased separation and retention for glutamate and glutamine compared to the CSH C₁₈ column. Moreover, the CSH fluoro phenyl column showed decreased separation and retention for glutamate and glutamine compared to both the CSH C₁₈ column and the CSH phenyl hexyl column.

[00131] **Example 3: Biomarkers**

[00132] Standards were prepared in water and diluted with water to make a solution of 100 µMolar for methylmalonic acid, aconitic acid, and succinic acid. Itaconic acid was made in a solution 10 µg/mL. These analytes were then separated using an ACQUITY® UPLC® I-Class LC system (commercially available from Waters Technologies Corporation, Milford, MA USA) coupled with a Xevo® TQ S tandem quadrupole mass spectrometer operated in ESI negative mode and in MRM acquisition mode (commercially available from Waters Technologies Corporation, Milford, MA USA). Details of the method are described in Tables 6 and 7.

TABLE 6: Liquid Chromatography Conditions

Columns	ACQUITY® UPLC® CSH C ₁₈ column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Phenyl-Hexyl column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Fluoro-Phenyl column; 130Å 1.7µm 2.1 x 100 mm (commercially available from Waters Technologies Corporation, Milford, MA USA)
Mobile Phase A	100% water, 0.1% formic acid (v/v)
Mobile Phase B	100% acetonitrile, 0.1% formic acid (v/v)
Column Temperature	50°C
Injection Volume	3µL
Sample Diluent	Water
Detection	Tandem quadrupole MS MRM mode ESI negative mode

TABLE 7: Gradient Table

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	0.40	100.0	0.00	Initial
3.00	0.40	70	30.0	6
3.50	0.40	5.0	95.0	6
6.50	0.40	5.0	95.0	6
7.00	0.40	100.0	0.0	6

[00133] FIGs. 10A-10D show the analysis of biomarkers using a CSH C₁₈ sorbent in a reversed phase column. FIG. 10A shows the MRM chromatogram for methylmalonic acid. FIG. 10B shows the MRM chromatogram for succinic acid. FIG. 10C shows the MRM chromatogram for aconitic acid. FIG. 10D shows the MRM chromatogram for itaconic acid.

[00134] FIGs. 11A-11D show the analysis of biomarkers using a CSH phenyl hexyl sorbent in a reversed phase column. FIG. 11A shows the MRM chromatogram for methylmalonic acid. FIG. 11B shows the MRM chromatogram for succinic acid. FIG. 11C shows the MRM chromatogram for aconitic acid. FIG. 11D shows the MRM chromatogram for itaconic acid.

[00135] FIGs. 12A-12D show the analysis of biomarkers using a CSH fluoro phenyl sorbent in a reversed phase column. FIG. 12A shows the MRM chromatogram for methylmalonic acid. FIG. 12B shows the MRM chromatogram for succinic acid. FIG. 12C shows the MRM chromatogram for aconitic acid. FIG. 12D shows the MRM chromatogram for itaconic acid.

[00136] Example 4: Phosphorylated Sugars

[00137] Glucose 6 phosphate standards were prepared in water and diluted with water to make a solution of 100 µMolar. This analyte, structure shown below, was then separated using an ACQUITY® UPLC® I-Class LC system (commercially available from Waters Technologies Corporation, Milford, MA USA) coupled with a Xevo® TQ S tandem quadrupole mass spectrometer operated in ESI negative mode and in


MRM acquisition mode (commercially available from Waters Technologies Corporation, Milford, MA USA). Details of the method are described in Tables 8 and 9.

TABLE 8: Liquid Chromatography Conditions

Columns	ACQUITY® UPLC® CSH C ₁₈ column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Phenyl-Hexyl column; 130Å 1.7µm 2.1 x 100 mm ACQUITY® UPLC® CSH Fluoro-Phenyl column; 130Å 1.7µm 2.1 x 100 mm (commercially available from Waters Technologies Corporation, Milford, MA USA)
Mobile Phase A	100% water, 0.1% formic acid (v/v)
Mobile Phase B	100% acetonitrile, 0.1% formic acid (v/v)
Column Temperature	50°C
Injection Volume	3µL
Sample Diluent	Water
Detection	Tandem quadrupole MS MRM mode ESI negative mode

TABLE 9: Gradient Table

Time (min)	Flow Rate (mL/min)	%A	%B	Curve
Initial	0.40	100.0	0.00	Initial
3.00	0.40	70	30.0	6
3.50	0.40	5.0	95.0	6
6.50	0.40	5.0	95.0	6
7.00	0.40	100.0	0.0	6



Glucose 6 phosphate structure

[00138] FIG. 13A shows the analysis of glucose 6 phosphate using a CSH C₁₈ sorbent in a reversed phase column. FIG. 13B shows the analysis of glucose 6 phosphate using a CSH phenyl hexyl sorbent in a reversed phase column. FIG. 13C shows the analysis of glucose 6 phosphate using a CSH fluoro phenyl sorbent in a reversed phase column. As can be seen from a comparison of these three stationary phase material, the CSH fluoro phenyl sorbent showed increased separation and retention as compared to the CSH phenyl hexyl stationary phase material, which showed increased separation and retention as compared to the CSH C₁₈ stationary phase material.

[00139] From all of these examples, it is shown that the anion-exchange characteristics of CSH columns make them useful for separating polar acidic analytes, which are typically poorly retained on reversed-phase columns.

[00140] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents were considered to be within the scope of this technology and are covered by the following claims. The contents of all references, issued patents, and published patent applications cited throughout this application are hereby incorporated by reference.

CLAIMS

What is claimed is:

1. A mixed-mode chromatography method for the determination of phosphorylated sugars in a sample, the mixed-mode chromatography method comprising:
 - obtaining a sample comprising at least one phosphorylated sugar;
 - introducing the sample onto a chromatography system comprising a column having a stationary phase material contained inside the column, the stationary phase material having a surface comprising a hydrophobic surface group and at least one ionizable modifier;
 - flowing the sample with a mobile phase eluent through the column, wherein the at least one phosphorylated sugar is substantially resolved and retained within seven minutes, the mobile phase eluent comprising water with an additive and acetonitrile with the additive, the mobile phase eluent having a pH less than 6; and
 - detecting the at least one phosphorylated sugar using a detector.
2. The mixed-mode chromatography method of claim 1, wherein the pH of the mobile phase eluent is less than 3.
3. The mixed-mode chromatography method of claim 2, wherein the pH of the mobile phase eluent is between about 2.5 and 3.
4. The mixed-mode chromatography method of claim 3, wherein the pH of the mobile phase eluent is about 2.7.
5. The mixed-mode chromatography method of claim 1, wherein the additive is 0.1% formic acid.
6. The mixed-mode chromatography method of claim 1, wherein the additive is a mass spectrometry compatible buffer.
7. The mixed-mode chromatography method of claim 1, wherein the mobile phase eluent comprises a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile.
8. The mixed-mode chromatography method of claim 7, wherein the mobile phase eluent has a linear or step gradient elution comprising
 - a. 100% mobile phase A, 0% mobile phase B at an initial time;
 - b. 70% mobile phase A, 30% mobile phase B at a time of 3 minutes;

- c. 5% mobile phase A, 95% mobile phase B at a time of 3.5 minutes;
 - d. 5% mobile phase A, 95% mobile phase B at a time of 6.5 minutes
 - e. 100% mobile phase A, 0% mobile phase B at a time of 7 minutes.
9. The mixed-mode chromatography method of claim 1, wherein the sample with the mobile phase eluent is flowed through the column at a rate from 0.2-1.0 mL/min.
10. The mixed-mode chromatography method of claim 9, wherein the sample with the mobile phase eluent is flowed through the column at a rate of about 0.4 mL/min.
11. The mixed-mode chromatography method of claim 1, wherein the hydrophobic surface group comprises a fluoro-phenyl functional group.
12. The mixed-mode chromatography method of claim 1, wherein the hydrophobic surface group comprises a phenyl-hexyl functional group.
13. The mixed-mode chromatography method of claim 1, wherein the hydrophobic surface group comprises a C₁₈ functional group.
14. The mixed-mode chromatography method of claim 1, wherein the detector is a mass spectrometer.
15. A mixed-mode chromatography method for the determination of amino acids in a sample, the mixed mode chromatography method comprising:
- obtaining a sample comprising at least one amino acid;
 - introducing the sample onto a chromatography system comprising a column having a stationary phase material contained inside the column, the stationary phase material having a surface comprising a hydrophobic surface group and at least one ionizable modifier;
 - flowing the sample with a mobile phase eluent through the column, wherein the at least one amino acid is substantially resolved and retained within seven minutes, the mobile phase eluent comprising water with an additive and acetonitrile with the additive, the mobile phase eluent having a pH less than 6; and
 - detecting the at least one amino acid using a detector.
16. The mixed-mode chromatography method of claim 15, wherein the pH of the mobile phase eluent is less than 3.
17. The mixed-mode chromatography method of claim 16, wherein the pH of the mobile phase eluent is between about 2.5 and 3.

18. The mixed-mode chromatography method of claim 17, wherein the pH of the mobile phase eluent is about 2.7.
19. The mixed-mode chromatography method of claim 15, wherein the additive is 0.1% formic acid.
20. The mixed-mode chromatography method of claim 15, wherein the additive is a mass spectrometry compatible buffer.
21. The mixed-mode chromatography method of claim 15, wherein the mobile phase eluent comprises a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile.
22. The mixed-mode chromatography method of claim 21, wherein the mobile phase eluent has a linear or step gradient elution comprising
- 100% mobile phase A, 0% mobile phase B at an initial time;
 - 70% mobile phase A, 30% mobile phase B at a time of 3 minutes;
 - 5% mobile phase A, 95% mobile phase B at a time of 3.5 minutes;
 - 5% mobile phase A, 95% mobile phase B at a time of 6.5 minutes
 - 100% mobile phase A, 0% mobile phase B at a time of 7 minutes.
23. The mixed-mode chromatography method of claim 15, wherein the sample with the mobile phase eluent is flowed through the mixed-mode column at a rate of about 0.2 - 1.0 - mL/min.
24. The mixed-mode chromatography method of claim 23, wherein the sample with the mobile phase eluent is flowed through the column at a rate of about 0.4 mL/min.
25. The mixed-mode chromatography method of claim 15, wherein the hydrophobic surface group comprises a fluoro-phenyl functional group.
26. The mixed-mode chromatography method of claim 15, wherein the hydrophobic surface group comprises a phenyl-hexyl functional group.
27. The mixed-mode chromatography method of claim 15, wherein the hydrophobic surface group comprises a C₁₈ functional group.

28. The mixed-mode chromatography method of claim 15, wherein the detector is a mass spectrometer.
29. The mixed-mode chromatography method of claim 15, wherein the at least one amino acid is glutamate, glutamine, isoleucine, or leucine.
30. A mixed-mode chromatography method for the determination of organic acids in a sample, the mixed mode chromatography method comprising:
- obtaining a sample comprising at least one organic acid;
 - introducing the sample onto a chromatography system comprising a column having a stationary phase material contained inside the column, the stationary phase material having a surface comprising a hydrophobic surface group having a fluoro-phenyl functional group and an ionizable modifier;
 - flowing the sample with a mobile phase eluent through the column, wherein the at least one organic acid is substantially resolved and retained within seven minutes, the mobile phase eluent comprising a mobile phase A consisting essentially of 0.1% formic acid in water and a mobile phase B consisting essentially of 0.1% formic acid in acetonitrile, the mobile phase eluent having a pH less than 6; and
 - detecting the at least one organic acid using a detector.
31. The mixed-mode chromatography method of claim 30, wherein the at least one organic acid is isocitric acid, aconitic acid, a-ketoglutaric acid, lactic acid, or pyruvic acid.

1/19




FIG. 1




FIG. 2

3/19

20F18_042 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

191.2 > 155.2

3.874e+006




FIG. 3A

20F18_042 Smooth(Mn,1x2)

citric acid

F2:MRM of 23 channels,ES-

191.2 > 87.1

5.229e+006




FIG. 3B

20F18_042 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

173 > 129

1.360e+007




FIG. 3C

4/19




FIG. 3D




FIG. 3E




FIG. 3F

5/19




FIG. 3G




FIG. 3H




FIG. 3I

6/19

20F18_075 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

191.2 > 155.2

3.398e+006




FIG. 4A

20F18_075 Smooth(Mn,1x2)

citric acid

F2:MRM of 23 channels,ES-

191.2 > 87.1

6.255e+006




FIG. 4B

20F18_075 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

173 > 129

1.185e+007




FIG. 4C

7/19




FIG. 4D




FIG. 4E




FIG. 4F

8/19




FIG. 4G




FIG. 4H




FIG. 4I

9/19

21F18_003 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

191.2 > 155.2

5.934e+005




FIG. 5A

21F18_003 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

191.2 > 87.1

2.329e+004




FIG. 5B

21F18_003 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

173 > 129

2.515e+006




FIG. 5C

10/19




FIG. 5D




FIG. 5E




FIG. 5F

11/19

21F18_003 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

115.2 > 71.3

1.477e+006




FIG. 5G

21F18_003 Smooth(Mn,1x2)

F2:MRM of 23 channels,ES-

89.2 > 43.2

1.066e+005




FIG. 5H

21F18_003 Smooth(Mn,1x2)

Pyruvate

F2:MRM of 23 channels,ES-

87.2 > 43.2

6.471e+003




FIG. 5I

12/19




FIG. 6A




FIG. 6B




FIG. 6C

13/19




FIG. 7A




FIG. 7B




FIG. 7C












FIG. 7D

14/19



TIME

15/19



16/19

METHYLMALONIC ACID 100 μ M

20F18_044 Sm (Mn, 1 x 2) F2


1.99 117.2 > 73.2
1.19e6

FIG. 10A

SUCCINIC ACID

20F18_042 Sm (Mn, 1 x 2) F2


1.08 117.2 > 73.2
4.09e6

FIG. 10B

20F18_065 Sm (Mn, 1 x 1) F2


173 > 129 (Aconitic Acid)
6.74e6

FIG. 10C

20F18_065 Sm (Mn, 1 x 1) F3


129.2 > 85.25 (Itaconic Acid)
5.88e6

FIG. 10D

17/19




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D

18/19




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D

19/19




FIG. 13A




FIG. 13B




FIG. 13C

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2019/056379

A. CLASSIFICATION OF SUBJECT MATTER

INV. B01D15/16 B01D15/20 B01D15/36 B01D15/38 G01N30/34
B01J20/281 G01N30/56 G01N30/72 B01D15/32 G01N30/96

ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

G01N B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JEFFREY A. CRUZ ET AL: "Metabolite profiling of Calvin cycle intermediates by HPLC-MS using mixed-mode stationary phases", THE PLANT JOURNAL, vol. 55, no. 6, 1 September 2008 (2008-09-01), pages 1047-1060, XP055644409, GB ISSN: 0960-7412, DOI: 10.1111/j.1365-313X.2008.03563.x	1-10,14
Y	abstract page 1048, column 2, paragraph 2 - page 1050, last paragraph; figures 2-3 "HPLC ion-trap MS"; page 1057 ----- -/--	8,11-13



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 November 2019

Date of mailing of the international search report

29/11/2019

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Meltaus, Johanna

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2019/056379

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GILAR M ET AL: "Mixed-mode chromatography for fractionation of peptides, phosphopeptides, and sialylated glycopeptides", JOURNAL OF CHROMATOGRAPHY A, ELSEVIER, AMSTERDAM, NL, vol. 1191, no. 1-2, 16 May 2008 (2008-05-16), pages 162-170, XP022647897, ISSN: 0021-9673, DOI: 10.1016/J.CHROMA.2008.01.061 [retrieved on 2008-01-31]	15-30
Y	abstract Last three paragraphs of the left column; sections 2.1 and 2.2; page 163 sections 3.1-3.3; paragraph bridging pages 168-169; page 164 - page 168 -----	11-13, 22,31
Y	RAAIDAH. SAARI-NORDHAUS ET AL: "Ion Chromatographic Separation of Inorganic Anions and Carboxylic Acids on a Mixed-Mode Stationary Phase", ANALYTICAL CHEMISTRY, vol. 64, no. 19, 1 October 1992 (1992-10-01), pages 2283-2287, XP055644721, US ISSN: 0003-2700, DOI: 10.1021/ac00043a018 abstract first paragraph under "Results and discussion"; page 2283, column 2 -----	31
Y	LUCIE NOVÁKOVÁ ET AL: "Evaluation of new mixed-mode UHPLC stationary phases and the importance of stationary phase choice when using low ionic-strength mobile phase additives", TALANTA, vol. 93, 1 May 2012 (2012-05-01), pages 99-105, XP055644004, NL ISSN: 0039-9140, DOI: 10.1016/j.talanta.2012.01.054 abstract 2.2 "Chromatography"; pages 101-102; figures 2-3 -----	8,22
X	WO 2017/117304 A1 (GENENTECH INC [US]; F HOFFMANN-LA ROCHE AG [CH]) 6 July 2017 (2017-07-06)	15,19, 21,28,30
Y	paragraph [0292]; table 1 -----	22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/IB2019/056379

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2017117304 A1	06-07-2017	AU 2016381694 A1	05-07-2018
		BR 112018013071 A2	11-12-2018
		CA 3007491 A1	06-07-2017
		CN 108430455 A	21-08-2018
		EP 3397243 A1	07-11-2018
		JP 2019501920 A	24-01-2019
		KR 20180093078 A	20-08-2018
		SG 11201804951S A	30-07-2018
		US 2017239355 A1	24-08-2017
		WO 2017117304 A1	06-07-2017
